By Ed Frankl 
 

Novartis said Friday that its prostate-cancer treatment 177Lu-PSMA-617 produced positive quality-of-life results in a Phase 3 study.

The treatment is an investigational targeted radioligand therapy to treat metastatic castration-resistant prostate cancer, Novartis said.

The Swiss pharmaceutical company said the Phase 3 Vision data showed delayed worsening of symptoms with 177Lu-PSMA-617 plus standard of care, compared to standard of care alone.

"These new data emphasize the potential impact on quality of life that investigational 177Lu-PSMA-617 may provide as a potential new treatment option," said Jeff Legos, global head of oncology development at Novartis.

The company in June received FDA breakthrough therapy designation for 177Lu-PSMA-617 in patients with prostate cancer.

 

Write to Ed Frankl at edward.frankl@dowjones.com

 

(END) Dow Jones Newswires

September 17, 2021 01:38 ET (05:38 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Novartis Charts.